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Fort Lauderdale, Florida once again hosted more 
than 10,000 ophthalmology and vision science 
researchers. The Association for Research in 
Vision and Ophthalmology (ARVO) annual 
meeting is well known for presentation of the 
latest milestones in fields related to vision 
science. ARVO is famous for being basic science 
oriented; clinical posters and papers, and even 
commercial exhibitions are markedly connected 
to molecular, immunologic and genetic aspects 
of disease and treatment modalities. Every year, 
ARVO brings established investigators and 
junior trainees from all over the world together 
and creates a unique environment to promote 
the next generation of ideas and idea makers. 
You can meet all the big names and researchers 
of tremendous insight at ARVO. For me, as a 
first-time attendee in such a science-oriented 
event, meeting colleagues and seeing such a 
wide range of state-of-the-art research was an 
invaluable experience.
ARVO is unique among other ophthalmology 
conferences for the non-formal attitude of the 
presenters and attendees. Even though the 
sessions are highly scientific in content and 
followed by challenging questions and answers, 
the casual attire of all attendees is eye catching 
at the very first look. 
With the recent developments in molecular 
biology, genetics, and diagnostic imaging 
technologies, it is not surprising that ARVO 
has focused on these fields during the past 
decade. This year’s meeting was named 
“Visionary Genomics” with particular emphasis 
on molecular and clinical genetic aspects in 
the presentation, diagnosis, and management 
of ocular disease.
One of the differences of ARVO from similar 
meetings is the importance of poster sessions 
in this event. More than one thousand posters 
a day and a total of five thousand posters, all 
presenting original research, were presented 
this year. Posters were organized into correlated 
topics making a full and in-depth review of 
the latest advances in a specific field possible. 
ARVO 2011 started on April 30, with a pre-
congress day consisting of a couple of symposia 
and ophthalmic association meetings. The 
American Uveitis Society annual meeting was 
held one day before ARVO with presentations 
from all around the world. At the beginning 
of this meeting, Dr Narsing A Rao delivered 
a lecture titled “Photoreceptor mitochondrial 
oxidative stress and its prevention in uveitis.” 
He presented the latest progress regarding the 
rapidly evolving role of micro-RNAs in uveitis, 
a major part of which has been developed 
during the past several years by his research 
group. Micro-RNAs are small non-coding 
post-translational regulators of mRNA to 
which they attach and result in translational 
repression or silencing of the genes. By use of 
validated micro-RNA mimics, immunologic 
pathways have been manipulated to suppress 
the expression of cytokine genes, leading to a 
reduction in inflammation. It seems that micro-
RNAs could be an important component of 
the next generation of therapeutic modalities.
The first day of ARVO 2011 was remarkable 
for the excellent presentation of “Innate and 
adaptive immunity in ocular defense and 
disease.” Our knowledge of the immune 
defense mechanisms in diverse conditions such 
as uveitis, allergy, transplantation rejection, 
tumor development, age-related macular 
degeneration (ARMD), and glaucoma has been 
improved immensely. We now know that these 
seemingly unrelated conditions are connected by 
common immunologic pathways and molecules. 
Overlapping mechanisms are creating a new News
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generalized overview towards these diseases. 
The possibility of modifying common basic 
mechanisms along with availability of individual 
whole genome sequencing will hopefully lead 
to individualized preventive and therapeutic 
approaches. 
Hot posters of the first day were too 
numerous to name, but included posters on 
nanobiodevices for drug delivery, artificial 
vision posters, individualized treatment 
modalities based on genetic testing, and new 
animal models for different ocular diseases.
I was able to attend some excellent oral 
presentations during the following days of 
ARVO 2011 and visit some posters and talk to 
their authors. Lectures and posters presenting 
results on ultrahigh resolution swept source- 
OCT (optical coherence tomography) imaging 
for measurement of retinal blood flow and 
oxygen tension, polarization sensitive-OCT, 
choroidal imaging with enhanced-depth OCT, 
VEGF (vascular endothelial growth factor) 
trap use for ARMD, real-time measurement 
of retinal temperature changes for calibration 
of laser power, complement factor H (CFH) 
polymorphism in primary open angle glaucoma 
(similar to what has previously been revealed 
for the CFH gene in ARMD), and results of 
various ARMD clinical trials were some of 
the interesting topics for me. Full access to the 
ARVO 2011 abstracts is possible through the 
official ARVO website (http://www.arvo.org).
Ocular inflammation and uveitis related 
studies were also exciting and mainly oriented 
towards the recognition of cellular components 
and molecular mediators of inflammation and 
possible mechanisms of their modulation for 
management of uveitis, the role of genetic 
factors (in particular micro-RNAs) in ocular 
inflammation, and results of various imaging 
techniques in uveitis syndromes. Long term 
results of immunomodulatory agents, including 
commercially available anti-TNF (anti-tumor 
necrosis factor) medications for management of 
intraocular inflammation, were also presented 
in the meeting.
On the last day of the meeting and in one 
of the main uveitis sessions, we presented 
our results on prognostic variables for 
uveitic epiretinal membranes (ERMs) with a 
morphometric spectral domain OCT approach; 
we showed that uveitic ERM thickness increases 
with time, even in clinically inactive eyes. These 
changes probably indicate ongoing subclinical 
inflammation which requires more aggressive 
treatment modalities to prevent long term 
complications.
Even though American or European-based 
Iranian ophthalmologists and basic science 
researchers had a significant contribution to 
the conference, very few Iranian colleagues 
attended this year’s ARVO. This limits our 
clinician-researcher society and eventually 
our patients from taking full advantage of this 
excellent scientific meeting. Next year’s ARVO 
meeting will be held on May 6-10, 2012 in Fort 
Lauderdale, Florida and we look forward to 
more presentations from Iran.